Shifting Perceptions of CRISPR

Shifting Perceptions of CRISPR

Photo by National Cancer Institute on Unsplash INTRODUCTION More than 20 cell and gene therapies are now available to safely minimize genetic diseases such as retinal dystrophy (LUXTURNA), some B-cell lymphomas (YESCARTA), and B-cell lymphoblastic leukemia (KYMRIAH).[1] One such gene-editing t...

Full description

Bibliographic Details
Main Author:	Camille Castelyn
Format:	Article
Language:	English
Published:	Columbia University Libraries 2021-08-01
Series:	Voices in Bioethics
Subjects:	Gene Therapy CRISPR COVID-19 Diagnostic Testing Public Health Clinical Trials
Online Access:	https://journals.library.columbia.edu/index.php/bioethics/article/view/8595

Similar Items

CRISPR/Cas-based Diagnostics and Gene Therapy
by: Meiyu Qiu, et al.
Published: (2021-11-01)

Current trends of clinical trials involving CRISPR/Cas systems
by: Songyang Zhang, et al.
Published: (2023-11-01)

Clinical applications of the CRISPR/Cas9 genome-editing system: Delivery options and challenges in precision medicine
by: Mohadeseh Khoshandam, et al.
Published: (2024-01-01)

Editing the human genome with CRISPR/Cas: a review of its molecular basis, current clinical applications, and bioethical implications
by: Miguel Ahumada-Ayala, et al.
Published: (2023-01-01)

Non-COVID-19 Patients Left out in the Cold
by: Camille Castelyn
Published: (2020-05-01)

Current developments of gene therapy in human diseases
by: Fanfei Liu, et al.
Published: (2024-09-01)

The power and the promise of CRISPR/Cas9 genome editing for clinical application with gene therapy
by: Ning Guo, et al.
Published: (2022-09-01)

Advancing CRISPR-Based Solutions for COVID-19 Diagnosis and Therapeutics
by: Roaa Hadi, et al.
Published: (2024-10-01)

Optimization of SARS-CoV-2 culture from clinical samples for clinical trial applications
by: Dominic Wooding, et al.
Published: (2024-11-01)

Capitalism is groovy, but at what cost?
by: Krishna Vedala, et al.
Published: (2020-11-01)

CRISPR/Cas9: implication for modeling and therapy of amyotrophic lateral sclerosis
by: Yajun Shi, et al.
Published: (2023-07-01)

CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future
by: Fathema Uddin, et al.
Published: (2020-08-01)

Advances in CRISPR-Cas technology and its applications: revolutionising precision medicine
by: Sarkar Sardar Azeez, et al.
Published: (2024-12-01)

SARS-CoV-2 Biochemistry, Transmission, Clinical Manifestations, and Prevention
by: Gundu H. R. Rao
Published: (2020-12-01)

Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation
by: Radwa Ewaisha, et al.
Published: (2023-02-01)

CRISPR technology in human diseases
by: Qiang Feng, et al.
Published: (2024-08-01)

Applications of CRISPR/Cas as a Toolbox for Hepatitis B Virus Detection and Therapeutics
by: Anuj Kumar, et al.
Published: (2024-10-01)

Targeting miRNA by CRISPR/Cas in cancer: advantages and challenges
by: Bashdar Mahmud Hussen, et al.
Published: (2023-07-01)

Oversight of biohacking when the stakes are high
by: Camille Castelyn
Published: (2020-03-01)

Editorial: CRISPR advancement in cancer research and future perspectives
by: Alessio Biagioni, et al.
Published: (2023-03-01)

Diagnostic randomized controlled trials: the final frontier
by: Rodger Marc, et al.
Published: (2012-08-01)

Reflections on the Application of Chinese Medicine During the Epidemic of COVID-19
by: Shaohui Geng, et al.
Published: (2022-12-01)

Intrinsic signal amplification by type III CRISPR-Cas systems provides a sequence-specific SARS-CoV-2 diagnostic
by: Andrew Santiago-Frangos, et al.
Published: (2021-06-01)

Rapid Detection of SARS-CoV-2 Based on the LAMP Assay Associated with the CRISPRCas12a System
by: Karoline Almeida Felix de Sousa, et al.
Published: (2023-06-01)

Gene editing and therapy – A new tool: CRISPR/Cas9
by: Ashok M. Patil
Published: (2019-07-01)

Type II CRISPR/Cas9 approach in the oncological therapy
by: A. Biagioni, et al.
Published: (2017-06-01)

CRISPR Gene-Therapy: A Critical Review of Ethical Concerns and a Proposal for Public Decision-Making
by: Victor Lange, et al.
Published: (2022-06-01)

CRISPR/Cas9-Mediated Gene Therapy for Glioblastoma: A Scoping Review
by: Emir Begagić, et al.
Published: (2024-01-01)

SARS-CoV-2 pandemics: An update of CRISPR in diagnosis and host–virus interaction studies
by: Wen-Fang Tang, et al.
Published: (2023-04-01)

Editorial: Regulation and governance of gene editing technologies (CRISPR, etc.)
by: Alberto Asquer, et al.
Published: (2022-09-01)

Development of Medicinal Products Based on Gene-Editing Technology: Regulatory Practices
by: N. S. Pokrovsky, et al.
Published: (2023-07-01)

COVID-19 clinical trial participation and awareness in Texas
by: Justin M. Luningham, et al.
Published: (2024-12-01)

Editorial: CRISPR: the game changer in gene and cell therapy
by: Wenxia He, et al.
Published: (2024-12-01)

CRISPR-Based Diagnostics for Point-of-Care Viral Detection
by: Alexander I. Mosa
Published: (2022-06-01)

Leadership in healthcare during a pandemic: for a systems leadership approach
by: Camille Castelyn, et al.
Published: (2024-05-01)

CRISPR delivery with extracellular vesicles: Promises and challenges
by: Anne Højberg Berggreen, et al.
Published: (2023-09-01)

CRISPR-Cas Systems: Prospects for Use in Medicine
by: Marina V. Zaychikova, et al.
Published: (2020-12-01)

CRISPR-Based Tools for Fighting Rare Diseases
by: Qingyang Li, et al.
Published: (2022-11-01)

CRISPR-based diagnostics of different biomolecules from nucleic acids, proteins, and small molecules to exosomes
by: Zhu Yuanshou, et al.
Published: (2023-08-01)

Can CRISPR/Cas Technology Be a Felicitous Stratagem Against the COVID-19 Fiasco? Prospects and Hitches
by: Rocktotpal Konwarh, et al.
Published: (2020-09-01)